Drugs by condition
Drugs approved for thyroid cancer
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
21
Still marketed, NDA or BLA
Drug classes
3
Novel drugs
9
New molecular entities and new biologics
In development
3
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for thyroid cancer.
- Retevmo (Selpercatinib) · Eli Lilly and CO OrphanApr 10, 2024
- Mekinist (Trametinib, Trametinib Dimethyl Sulfoxide) · Novartis Priority reviewOrphanMar 16, 2023
- Tafinlar (Dabrafenib Mesylate) · Novartis Breakthrough therapyPriority reviewOrphanMar 16, 2023
- Thyquidity (Levothyroxine Sodium) · Stevens J Nov 30, 2020
- Gavreto (Pralsetinib) · Rigel Pharms NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanSep 4, 2020
All approved drugs for thyroid cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 14 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (5)
Thyroid Stimulating Hormone (1)
- Thyrogen Thyrotropin Alfa · Genzyme · 1998
Class not listed in FDA's data (15)
- Tafinlar Dabrafenib Mesylate · Novartis · 2013
- Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
- Cometriq Cabozantinib S-Malate · Exelixis · 2012
- Cytomel Liothyronine Sodium · King Pharms · 1956
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
- Tafinlar Dabrafenib Mesylate · Novartis · 2023
- Thyquidity Levothyroxine Sodium · Stevens J · 2020
- Tirosint-Sol Levothyroxine Sodium · Ibsa · 2016
- Cabometyx Cabozantinib S-Malate · Exelixis INC · 2016
- Tirosint Levothyroxine Sodium · Ibsa · 2006
- Thyro-Tabs Levothyroxine Sodium · Alvogen · 2002
- Synthroid Levothyroxine Sodium · Abbvie · 2002
- Levo-T Levothyroxine Sodium · Cediprof INC · 2002
- Levoxyl Levothyroxine Sodium · King Pharms · 2001
- Unithroid Levothyroxine Sodium · Stevens J · 2000
Drugs in development for thyroid cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AL2846Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer
- XP-102Phase 21 trial
Xynomic Pharmaceuticals, Inc. · Cancer, BRAF V600 Mutation, Melanoma
More on thyroid cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.